Huntingtin processing in pathogenesis of Huntington disease

被引:0
|
作者
Zheng-hong QIN
Laboratory of Cellular Neurobiology
机构
关键词
<Keyword>Huntington disease; huntingtin; caspase; calpain; proteasome; protein aggregation; autophagy; neurodegeneration;
D O I
暂无
中图分类号
R742.2 [舞蹈病];
学科分类号
摘要
Huntington’s disease (HD) is caused by an expansion of the polyglutamine tract in the protein named huntingtin. The expansion of polyglutamine tract induces selective degeneration of striatal projection neurons and cortical pyramidal neurons. The bio-hallmark of HD is the formation of intranuclear inclusions and cytoplasmic aggregates in association with other cellular proteins in vulnerable neurons. Accumulation of N-terminal mutant huntingtin in HD brains is prominent. These pathological features are related to protein misfolding and impairments in protein processing and degradation in neurons. This review focused on the role of proteases in huntingtin cleavage and degradation and the contribution of altered processing of mutant huntingtin to HD pathogenesis.
引用
收藏
页码:3 / 9
页数:7
相关论文
共 50 条
  • [21] Nucleocytoplasmic transport of huntingtin and Huntington's disease
    Truant, R
    CLINICAL NEUROSCIENCE RESEARCH, 2003, 3 (03) : 157 - 164
  • [22] ARGININE METHYLATION OF HUNTINGTIN IS A NOVEL POST-TRANSLATIONAL MODIFICATION THAT IMPACTS HUNTINGTON'S DISEASE PATHOGENESIS
    Migazzi, Alice
    Tripathy, Debasmita
    Scaramuzzino, Chiara
    Pandey, Udai Bhan
    Saudou, Frederic
    Pennuto, Maria
    Basso, Manuela
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 : A5 - A6
  • [23] HAP40 is a conserved central regulator of Huntingtin and a potential modulator of Huntington's disease pathogenesis
    Xu, Shiyu
    Li, Gang
    Ye, Xin
    Chen, Dongsheng
    Chen, Zhihua
    Xu, Zhen
    Daniele, Moretti
    Tambone, Sara
    Ceccacci, Alessandra
    Tomei, Licia
    Ye, Lili
    Yu, Yue
    Solbach, Amanda
    Farmer, Stephen M.
    Stimming, Erin Furr
    McAllister, George
    Marchionini, Deanna M.
    Zhang, Sheng
    PLOS GENETICS, 2022, 18 (07):
  • [24] Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease
    Tabrizi, Sarah J.
    Ghosh, Rhia
    Leavitt, Blair R.
    NEURON, 2019, 101 (05) : 801 - 819
  • [25] Huntingtin-lowering strategies for Huntington's disease
    Barker, Roger A.
    Fujimaki, Motoki
    Rogers, Priya
    Rubinsztein, David C.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (10) : 1125 - 1132
  • [26] Huntington's disease: Huntingtin and the control of axonal transport
    Zala, D.
    Liot, G.
    Humbert, S.
    Saudou, F.
    JOURNAL OF NEUROCHEMISTRY, 2009, 110 : 60 - 60
  • [27] Targeting Huntingtin in Patients with Huntington's Disease Reply
    Tabrizi, Sarah J.
    Smith, Anne V.
    Bennett, C. Frank
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (12): : 1181 - 1182
  • [28] Role of wild type huntingtin in Huntington's disease
    Cattaneo, E
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76
  • [29] SUMO modification of Huntingtin and Huntington's disease pathology
    Steffan, JS
    Agrawal, N
    Pallos, J
    Rockabrand, E
    Trotman, LC
    Slepko, N
    Illes, K
    Lukacsovich, T
    Zhu, YZ
    Cattaneo, E
    Pandolfi, PP
    Thompson, LM
    Marsh, JL
    SCIENCE, 2004, 304 (5667) : 100 - 104
  • [30] Targeting Huntingtin Expression in Patients with Huntington's Disease
    Tabrizi, Sarah J.
    Leavitt, Blair R.
    Landwehrmeyer, G. Bernhard
    Wild, Edward J.
    Saft, Carsten
    Barker, Roger A.
    Blair, Nick F.
    Craufurd, David
    Priller, Josef
    Rickards, Hugh
    Rosser, Anne
    Kordasiewicz, Holly B.
    Czech, Christian
    Swayze, Eric E.
    Norris, Daniel A.
    Baumann, Tiffany
    Gerlach, Irene
    Schobel, Scott A.
    Paz, Erika
    Smith, Anne V.
    Bennett, C. Frank
    Lane, Roger M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24): : 2307 - 2316